Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06803888 · ClinicalTrials.gov registry record · Phase 4
Bariatric Surgery vs. Semaglutide vs. Tirzepatide
A Phase 4 study of Obesity and Obesity-related Medical Conditions, sponsored by Ali Aminian.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT06803888 is a Phase 4 study of Obesity and Obesity-related Medical Conditions that is actively recruiting participants, run by Ali Aminian. The registered enrollment target is 125 participants, below the 528-participant average among 13 other Obesity and Obesity-related Medical Conditions trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06803888, a Phase 4 study of Obesity and Obesity-related Medical Conditions, is actively recruiting participants, sponsored by Ali Aminian.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
The recent introduction of the new generation of anti-obesity medications (AOMs) will change the future of obesity treatment. These highly effective medications, such as high-dose semaglutide and tirzepatide, are hormone analogues that augment the incretin function and exert multiple physiological effects by activating glucagon-like peptide-1 (GLP-1) and/or glucose-dependent insulinotropic polypeptide (GIP) distributed in various organs. These medications provide an average of 15-22% weight reduction in one-year trials, which had not been seen in the past with medical therapy. While the literature suggests that bariatric surgery is superior to these new highly effective medications, there is no head-to-head comparison between the most common bariatric operations (Roux-en-Y gastric bypass \[RYGB\] and sleeve gastrectomy \[SG\]) with semaglutide (once weekly) and tirzepatide (once weekly). The goal of this Randomized Clinical Trial (RCT) is to compare these effective therapies in patients with severe obesity to provide the best evidence to inform clinical decisions in treating patients with obesity.
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Semaglutide
- PROCEDURE Bariatric Surgery
Study Locations (1)
Ohio
- The Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2025-01-29 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06803888
The ClinicalTrials.gov registry entry for NCT06803888 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 528-participant average among 13 other Obesity and Obesity-related Medical Conditions trials with a reported enrollment target (76% lower). The listed sponsor is Ali Aminian, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity and Obesity-related Medical Conditions appearing as the primary indexed condition, and to 3 interventions - of which Tirzepatide is the first listed.
NCT06803888 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06803888 about?
NCT06803888 is a clinical study titled "Bariatric Surgery vs. Semaglutide vs. Tirzepatide". The recent introduction of the new generation of anti-obesity medications (AOMs) will change the future of obesity treatment. These highly effective medications, such as high-dose semaglutide and tirzepatide, are hormone analogues that augment the incretin function and exert multiple physiological e...
What is the current status of trial NCT06803888?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 125 participants. The study started on 2025-01-29. Estimated completion is 2027-12-01.
What conditions does trial NCT06803888 study?
This clinical trial studies the following conditions: Obesity and Obesity-related Medical Conditions.
What interventions are being tested in trial NCT06803888?
The interventions under investigation include: Tirzepatide (DRUG), Semaglutide (DRUG), Bariatric Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT06803888?
This trial is sponsored by Ali Aminian, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06803888 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity and Obesity-related Medical Conditions
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
2024 Tirzepatide-Bariatric Surgery
RECRUITING · Phase 4
-
Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy
RECRUITING · NA
-
Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss
RECRUITING
-
New Mechanisms of Obesity
RECRUITING · NA
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.